CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.42
-0.01 (-1.33%)
▼
5d:
-11.32%
30d:
-26.78%
90d:
-24.93%
WAIT
LOW Confidence
Analysis Updated: Oct 20, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CTXR is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CTXR is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.42, which is considered oversold relative to its 30-day fair value range of $0.49 to $0.58. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.3) compared to its historical average (0.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTXR is in a uptrend. The price is currently testing key support at $0.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CTXR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+835.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTXR is in a uptrend. The price is currently testing key support at $0.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CTXR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+835.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.49 -
$0.58
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 835.0% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.49 -
$0.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.41
Resistance Level
$0.53
Current Trend
Uptrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.30
Wall Street Target
$4.00
(+835.0%)
PE vs Historical
-0.3 vs 0.3
CHEAP
Share & Embed Analysis
Last updated: October 20, 2026 11:59 AM ET
Data refreshes hourly during market hours. Next update: 12:59 PM
Data refreshes hourly during market hours. Next update: 12:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 67 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 73 BUY |
|
PTGX
Protagonist Therapeutics… |
STRONG BUY
14 analysts |
$178 | 70 BUY |
